Sionna Therapeutics, Inc. Common Stock
$7.04
$0.16 (+2.33%)
$6.91Day Range$7.37
Key Statistics
Market Cap
$311.06M
Shares Outstanding
45.2M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Feb 7, 2025
Round Lot
100
Locale
US
Trading Data
Day Open
$6.95
Day High
$7.37
Day Low
$6.91
Volume
1.97M
VWAP
$7.11
Prev Close
$6.88
Transactions
--
Acc. Volume
--
About Sionna Therapeutics, Inc. Common Stock
Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefits to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.
PHARMACEUTICAL PREPARATIONSSIC 283459 employees21 HICKORY DRIVE, SUITE 500, WALTHAM, MA, 02451617-819-2020IPO Feb 7, 2025US / STOCKSActiveWebsite
Identifiers
- CIK
- 0002036042
- Composite FIGI
- BBG016X2DC85
- Share Class FIGI
- BBG016X2DCF7
- Ticker Root
- SION
- SIC Code
- 2834
About Sionna Therapeutics, Inc. Common Stock (SION) Stock
Sionna Therapeutics, Inc. Common Stock (SION) closed the 2026-09-16 session at $7.04, up 2.33% versus the previous close (+0.16). The stock opened at $6.95 and traded between $6.91 and $7.37 during that session. Session trading volume was 2.0M shares. The volume-weighted average price (VWAP) is $7.11.
Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefits to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.
Sionna Therapeutics, Inc. Common Stock has a market capitalization of $311.1 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. SION is listed on the XNAS exchange. The company employs approximately 59 people. Sionna Therapeutics, Inc. Common Stock is headquartered in WALTHAM, MA. The recorded listing date is 2025-02-07.
On this page you can find market SION stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.